Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
PeptiDream Inc (PeptiDream) is a biopharmaceutical company discovering and developing macrocyclic peptides. The company pipeline products include 18F-Flortaucipir for alzheimer’s disease, 177Lu/64Cu-PSMA I&T treats prostate cancer, 64Cu-ATSM for the treatment of malignant brain tumors and others. Its developing pipeline including 177Lu-Integrin, 225Ac/68Ga-GPC3, 177Lu/68Ga Program, 225Ac/64Cu-CA9, 225Ac/64Cu-CLDN18.2 and 225Ac-Cadherin3 for the indication of solid tumor, gastric cancer, renal cell carcinoma, hepatocellular carcinoma, malignant glioma, among others. The company’s Peptide Discovery Platform System (PDPS) technology used in research and development. It works in collaboration with Eli Lilly, Bristol-Myers Squibb, Amolyt Pharma, AstraZeneca, Biohaven, Merc and Alivexis. PeptiDream is headquartered in Kawasaki, Kanagawa, Japan.
Headquarters
Japan
Address
3-25-23, Tono-Machi, Kawasaki-Ku, Kanagawa, 210-0821
Website
www.peptidream.com
Telephone
81 44 2236612
No of Employees
751
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4587 (TYO)
Revenue (2024)
$119.0M
-60.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-125%
(2024 vs 2023)
Market Cap*
$855.7M
Net Profit Margin (2024)
XYZ
-162.9%
(2024 vs 2023)
* As of and is in US$
PeptiDream Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| 64Cu-ATSM: Malignant Brain Tumors |
| 177Lu/68Ga-Integrin: Malignant Glioma |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | PeptiDream Inc | AnGes Inc | OncoTherapy Science Inc | BrightPath Biotherapeutics Co Ltd | Jitsubo Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Kawasaki | Ibaraki | Kawasaki | Chiyoda-Ku | Yokohama |
| State/Province | Kanagawa | Osaka | Kanagawa | Tokyo | Kanagawa |
| No. of Employees | 751 | 56 | 47 | 24 | 15 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Patrick C Reid, Ph.D. | Director; Chief Executive Officer | Executive Board | - | - |
| Masato Murakami MD, Ph.D. | President; Chief Medical Officer; Director | Executive Board | 2024 | - |
| Christian Cunningham Ph.D. | Chief Scientific Officer | Senior Management | 2024 | - |
| Junko Utsunomiya | Director | Non Executive Board | 2021 | - |
| Yukinori Hanafusa | Director | Non Executive Board | 2016 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer